Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation and Depletion (2016 - 2020)

Historic Depreciation and Depletion for Agios Pharmaceuticals (AGIO) over the last 9 years, with Q2 2020 value amounting to $2.4 million.

  • Agios Pharmaceuticals' Depreciation and Depletion rose 1939.13% to $2.4 million in Q2 2020 from the same period last year, while for Jun 2020 it was $8.9 million, marking a year-over-year increase of 1396.25%. This contributed to the annual value of $5.2 million for FY2025, which is 877.19% down from last year.
  • As of Q2 2020, Agios Pharmaceuticals' Depreciation and Depletion stood at $2.4 million, which was up 1939.13% from $2.5 million recorded in Q1 2020.
  • In the past 5 years, Agios Pharmaceuticals' Depreciation and Depletion ranged from a high of $2.5 million in Q1 2020 and a low of $1.2 million during Q1 2016
  • Over the past 5 years, Agios Pharmaceuticals' median Depreciation and Depletion value was $1.7 million (recorded in 2018), while the average stood at $1.8 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Depreciation and Depletion soared by 23675.68% in 2016 and then crashed by 580.72% in 2017.
  • Agios Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $1.7 million in 2016, then fell by 5.81% to $1.6 million in 2017, then increased by 19.54% to $1.9 million in 2018, then dropped by 3.25% to $1.9 million in 2019, then increased by 29.64% to $2.4 million in 2020.
  • Its last three reported values are $2.4 million in Q2 2020, $2.5 million for Q1 2020, and $1.9 million during Q4 2019.